Recombinant Mouse Acot12 Protein, Myc/DDK-tagged
Cat.No. : | Acot12-1498M |
Product Overview : | Purified recombinant protein of mouse full-length acyl-CoA thioesterase 12 (Acot12), with C-terminal MYC/DDK tag, expressed in HEK293T cells. |
- Specification
- Gene Information
- Related Products
- Download
Description : | Biased expression in liver adult (RPKM 18.2), kidney adult (RPKM 14.7) and 8 other tissues |
Source : | HEK293T |
Species : | Mouse |
Tag : | Myc/DDK |
Molecular Mass : | 61.8 kDa |
Purity : | > 80% as determined by SDS-PAGE and Coomassie blue staining |
Stability : | Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. |
Storage : | Store at -80 centigrade after receiving vials. |
Concentration : | >50 μg/mL as determined by microplate BCA method |
Storage Buffer : | 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol. |
Gene Name : | Acot12 acyl-CoA thioesterase 12 [ Mus musculus (house mouse) ] |
Official Symbol : | Acot12 |
Synonyms : | ACOT12; acyl-CoA thioesterase 12; acyl-coenzyme A thioesterase 12; CACH-1; cytosolic acetyl-CoA hydrolase; acyl-CoA thioester hydrolase 12; cytoplasmic acetyl-CoA hydrolase 1; Cach; mCACH-1; AV027244; 1300004O04Rik; 4930449F15Rik |
Gene ID : | 74156 |
mRNA Refseq : | NM_028790 |
Protein Refseq : | NP_083066 |
UniProt ID : | Q9DBK0 |
Products Types
◆ Recombinant Protein | ||
ACOT12-113R | Recombinant Rat ACOT12 Protein, His (Fc)-Avi-tagged | +Inquiry |
ACOT12-9297H | Recombinant Human ACOT12, His-tagged | +Inquiry |
ACOT12-168H | Recombinant Human ACOT12 Protein, GST-Tagged | +Inquiry |
ACOT12-457R | Recombinant Rat ACOT12 Protein | +Inquiry |
◆ Lysates | ||
ACOT12-9090HCL | Recombinant Human ACOT12 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (12)
Ask a questionThere are currently no known clinical trials of ACOT12-targeted therapies. However, as this area of research continues to develop, it is possible that clinical trials may be initiated in the future.
The expression of ACOT12 is regulated by various factors, including hormones and nutrients. For example, insulin can upregulate ACOT12 expression in adipose tissue and liver, while fasting can downregulate it. Additionally, dietary factors such as fatty acids and carbohydrates can affect ACOT12 expression in various tissues.
The potential benefits of using ACOT12 protein in drug development include the ability to develop drugs that can regulate lipid metabolism, which can lead to improved treatment options for metabolic disorders such as obesity and diabetes. Additionally, ACOT12 protein can be used as a target for drug discovery, which can lead to the development of new and effective drugs for these conditions.
As with any drug development process, there may be potential risks associated with the use of ACOT12 protein. For example, targeting ACOT12 protein may lead to unintended effects and harm to other metabolic processes. However, these risks can be minimized through careful research, testing, and regulation of drug development.
ACOT12 protein can be produced using recombinant DNA technology in bacteria or mammalian cells. The protein can be purified using various chromatography techniques and verified using assays to ensure its activity and purity.
The potential risks and concerns associated with ACOT12-targeted therapies are not yet fully understood and would depend on the specific targeting strategy used. For example, small molecule inhibitors can have off-target effects and may interact with other drugs, while biologics can have immunogenicity and other safety concerns. Additionally, long-term effects of targeting ACOT12 are still unclear and require further research.
It is possible that ACOT12-targeted therapies could be used as preventive measures for metabolic disorders, especially in at-risk populations. However, more research is needed to determine the optimal timing and dosing of these therapies for maximum benefit.
ACOT12 protein may be used in drug development for metabolic disorders such as obesity and diabetes. The enzyme's role in regulating lipid metabolism makes it a potential target for drug development. Compounds that can modulate ACOT12 activity may be developed to treat these conditions.
ACOT12 can potentially be targeted with small molecule inhibitors or activators, as well as with biologics such as monoclonal antibodies or RNA-based therapeutics. However, more research is needed to identify the most effective and specific targeting strategies for this protein.
ACOT12 protein is used in both research and industry settings. In research, ACOT12 protein is often used to study lipid metabolism, obesity, diabetes, and other metabolic disorders. In industry, ACOT12 protein may be used in the development of drugs that target lipid metabolism and metabolic diseases.
There have been some studies investigating natural compounds that may have an effect on ACOT12 activity. For example, certain flavonoids found in citrus fruits and green tea have been shown to inhibit ACOT12 in vitro. However, further research is needed to determine the effectiveness and safety of using natural compounds to target ACOT12 in vivo.
ACOT12 protein is known to play a role in lipid metabolism and may have potential applications in the treatment of metabolic disorders such as obesity and type 2 diabetes. Additionally, ACOT12 has been implicated in the regulation of autophagy and oxidative stress, suggesting a potential role in the treatment of neurodegenerative diseases and cancers.
Ask a Question for All Acot12 Products
Required fields are marked with *
My Review for All Acot12 Products
Required fields are marked with *
Inquiry Basket